Lifeward Regains Nasdaq Listing, Pivots From Survival to Innovation

HUDSON, MA – March 11, 2026 – Lifeward Ltd. (Nasdaq: LFWD), a developer of life-changing medical technologies, announced today that it has successfully regained compliance with Nasdaq's minimum bid price requirement, securing its position on the exchange and closing a chapter of significant financial uncertainty.

The notification from The Nasdaq Stock Market LLC confirms that the company has resolved a deficiency that had placed it at risk of being delisted. This development removes a major operational hurdle, allowing management to shift its full attention from market compliance back to its core mission of advancing technology for individuals with physical disabilities.

A Seven-Month Battle for Compliance

The company’s struggle began on August 5, 2025, when it received a deficiency notice from Nasdaq. The notification stated that Lifeward's common stock had closed below the required minimum of $1.00 per share for 30 consecutive business days, putting it in violation of Nasdaq Listing Rule 5550(a)(2). This triggered a 180-day grace period, a countdown to February 2, 2026, for the company to rectify the situation or face potential delisting—a move that could have severely hampered its access to capital and damaged investor confidence.

The stock price slump was not an isolated event but rather a symptom of deeper financial pressures. As ReWalk Robotics, its former corporate identity, the company has a history of wrestling with profitability. Public filings and market analysis from the period pointed to challenges including negative cash flows, shrinking equity, and a year-over-year decline in net income. These persistent financial headwinds contributed to the erosion of its stock value, a recurring issue that also saw the company face a similar compliance battle back in 2018, which it resolved through a reverse stock split.

History repeated itself. To engineer a recovery, Lifeward's management executed a critical strategic maneuver. On February 20, 2026, the company announced a 1-for-12 reverse stock split. This corporate action consolidated the number of outstanding shares, artificially boosting the price of each individual share. The strategy proved effective. Beginning on February 24, the company’s stock began a sustained climb, maintaining a closing price at or above the $1.00 threshold for the required 10 consecutive business days, culminating in its successful compliance on March 9, 2026.

Refocusing on a Mission-Driven Future

With the immediate threat of delisting averted, Lifeward is aggressively pivoting back to the innovation that defines its brand. The company's portfolio, which includes the flagship ReWalk Personal Exoskeleton, the AlterG Anti-Gravity System, and the ReStore Exo-Suit, is central to its mission of transforming the lives of people with physical limitations. Now, freed from the distraction of its Nasdaq compliance battle, the company is visibly accelerating its strategic growth initiatives.

Just last week, on March 2, Lifeward announced a significant collaboration with the Shirley Ryan AbilityLab, one of the world's premier rehabilitation research hospitals. The partnership is designed to expand patient access to the ReWalk Personal Exoskeleton, a wearable robotic device that enables individuals with spinal cord injuries to stand, walk, and navigate stairs. This move signals a renewed push to deepen its market penetration and reinforce the clinical value of its core products.

Furthermore, the company is actively expanding its technological horizons. On February 25, Lifeward announced its intention to acquire the assets and technology for a powered upper-body exoskeleton from Skelable. This new device leverages artificial intelligence and is designed to help restore arm and hand function for stroke survivors, a massive and underserved patient population. The planned acquisition underscores Lifeward's commitment to broadening its product ecosystem to address a wider continuum of care in physical rehabilitation.

Market Confidence and Lingering Questions

The market has reacted positively to Lifeward's restored Nasdaq compliance. The resolution eliminates a significant risk factor that may have deterred institutional investors and suppressed trading activity. Analyst sentiment reflects cautious optimism, with a consensus "Buy" rating and a median price target suggesting considerable upside from its current valuation. The successful navigation of this compliance challenge is seen as a testament to management's ability to protect shareholder value under pressure.

However, the reverse stock split, while effective, does not by itself solve the underlying financial performance issues that initially caused the stock price to decline. Investors and analysts will now be watching closely to see if the company's renewed strategic focus can translate into sustainable revenue growth and a clear path to profitability. The company's debt has reportedly decreased significantly year-over-year, offering a positive sign for its balance sheet.

The next major indicator of the company's health will come on March 18, 2026, when Lifeward is scheduled to report its fourth-quarter and full-year 2025 financial results. That report will provide the first comprehensive look at the company's financial standing post-compliance and offer critical insights into whether its operational and strategic initiatives are beginning to yield tangible financial returns.